Ashwin Balagopal, MD

• Chair, ACTG 5335s
• Investigator ACTG 5329 and ACTG 5334s
• Investigator, Hepatitis Transformative Science Group (Feb 2016)

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

P1078 is a Phase IV, randomized, double-blind, placebo-controlled study of HIV-infected pregnant women and the infants born to...

Johns Hopkins University Baltimore-India Clinical Trials Unit